We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+35.19%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$336M
AUM Growth
+$28.4M
Cap. Flow
-$47.2M
Cap. Flow %
-14.05%
Top 10 Hldgs %
56.86%
Holding
90
New
10
Increased
16
Reduced
26
Closed
16

Top Buys

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$4.4M
2
FLNA
Filana Therapeutics
FLNA
+$4.02M
3
VERO
Venus Concept
VERO
+$3.39M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$2.94M
5
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$2.73M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$22.2M
2
ARCT icon
Arcturus Therapeutics
ARCT
+$9.85M
3
FATE icon
Fate Therapeutics
FATE
+$6.46M
4
BEAT
BioTelemetry, Inc.
BEAT
+$2.89M
5
BPMC
Blueprint Medicines
BPMC
+$2.76M

Sector Composition

Rank Sector Weight
1 Healthcare 89.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FLNA
26
Filana Therapeutics
FLNA
$46.3M
$3.07M 0.91%
+450,000
New +$4.02M
CNST
27
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$2.9M 0.86%
100,594
-80,348
-44% -$2.02M
HOOK
28
DELISTED
HOOKIPA Pharma
HOOK
$2.77M 0.83%
25,000
+22,794
+1,033% +$2.46M
KNTE
29
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$2.71M 0.81%
+68,121
New +$2.73M
VERO
30
DELISTED
Venus Concept
VERO
$2.6M 0.77%
+9,091
New +$3.39M
ETNB
31
DELISTED
89bio
ETNB
$2.57M 0.76%
105,478
-5,000
-5% -$128K
VKTX icon
32
Viking Therapeutics
VKTX
$3.88B
$2.57M 0.76%
455,900
+5,000
+1% +$30.3K
OTIC
33
DELISTED
Otonomy, Inc.
OTIC
$2.52M 0.75%
389,592
-299,508
-43% -$1.36M
APLS
34
DELISTED
Apellis Pharmaceuticals
APLS
$2.51M 0.75%
43,916
+13,862
+46% +$586K
MREO
35
Mereo BioPharma
MREO
$48.8M
$2.39M 0.71%
668,148
+468,723
+235% +$1.17M
MORF
36
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$2.06M 0.61%
+61,467
New +$1.82M
KDMN
37
DELISTED
Kadmon Holdings, Inc.
KDMN
$1.95M 0.58%
470,361
-93,203
-17% -$368K
ALEC icon
38
Alector
ALEC
$203M
$1.93M 0.57%
127,500
-12,500
-9% -$155K
STRO icon
39
Sutro Biopharma
STRO
$400M
$1.84M 0.55%
8,500
-3,394
-29% -$562K
LITS
40
Lite Strategy Inc
LITS
$31.6M
$1.82M 0.54%
34,550
+1,250
+4% +$72.1K
PRVL
41
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$1.73M 0.51%
75,000
– –
NTUS
42
DELISTED
Natus Medical Inc
NTUS
$1.72M 0.51%
85,575
+42,675
+99% +$836K
LQDA icon
43
Liquidia Corp
LQDA
$7.95B
$1.7M 0.5%
575,000
– –
KRTX
44
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$1.69M 0.5%
16,668
+7,437
+81% +$689K
FSDC
45
DELISTED
FS Development Corp. Class A Common Stock
FSDC
$1.65M 0.49%
+150,000
New +$1.55M
SCYX icon
46
SCYNEXIS
SCYX
$51.6M
$1.53M 0.46%
+25,000
New +$1.17M
JNJ icon
47
Johnson & Johnson
JNJ
$619B
$1.48M 0.44%
9,400
– –
ALPN
48
DELISTED
Alpine Immune Sciences Inc
ALPN
$1.43M 0.42%
113,202
-35,058
-24% -$344K
HARP
49
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$1.41M 0.42%
8,512
– –
CGEN icon
50
Compugen
CGEN
$218M
$1.4M 0.42%
115,202
– –
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return

DAFNA Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, DAFNA Capital Management held 90 positions worth $336M, up 9.2% from $308M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

DAFNA Capital Management withdrew a net $47.2M in Q4 2020, closing 16 positions and reducing 26 holdings. Its most notable exit was Immunomedics Inc, an estimated $22.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 83% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in Filana Therapeutics worth $3.07M.

  • DAFNA Capital Management's largest Q4 2020 buy was Filana Therapeutics: 450,000 shares worth $3.07M.
  • DAFNA Capital Management added most to Lakefront Biotherapeutics American Depositary Shares in Q4 2020, an estimated $4.4M increase.
  • DAFNA Capital Management's biggest Q4 2020 reduction was Fate Therapeutics, cutting an estimated $6.46M.
  • DAFNA Capital Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $22.2M.
  • DAFNA Capital Management's ten largest holdings make up 57% of its $336M portfolio in Q4 2020.
  • DAFNA Capital Management opened 10 new positions and closed 16 in Q4 2020.
  • DAFNA Capital Management's portfolio value rose 9.2% quarter-over-quarter to $336M.

Based on DAFNA Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.